- Cellmid signed a collaboration agreement with Abcodia for testing midkine in longitudinal serum samples
- Abcodia has exclusive access to a unique collection of 5,000,000 serum samples
- Initially targeting validation of midkine as early marker of colorectal cancer.
SYDNEY, Monday, 29 July 2013: Cellmid Limited (ASX:CDY) signed a collaboration agreement with Abcodia Ltd, the UK biomarker validation company, for the testing of midkine (MK) in their collection of longitudinal serum samples using Cellmid’s MK- ELISA.
The initial objective of the collaboration is to validate midkine as a useful marker for the screening and early diagnosis of colorectal cancer. Serum samples will be provided by Abcodia and testing will be carried out by Cellmid.
The collaboration focuses on the assessment of midkine in pre-diagnosis serum samples. Abcodia has exclusive access to a unique biobank of 5,000,000 serum samples collected through the UK Collaborative Trial for Ovarian Cancer Screening.
For further information please download PDF below:
